Visfatin mediates doxorubicin resistance in human non-small-cell lung cancer via Akt-mediated up-regulation of ABCC1.
作者： Zhili Cao , Naixin Liang , Huaxia Yang , Shanqing Li
DOI: 10.1111/CPR.12366
关键词: Cancer research 、 Regulation of gene expression 、 Lung cancer 、 Cell culture 、 Downregulation and upregulation 、 Doxorubicin 、 ABCC1 、 Chemistry 、 Protein kinase B 、 Gene knockdown
摘要: Objectives Non-small-cell lung cancer (NSCLC) is one of the leading causes deaths worldwide. Increasing levels visfatin are correlated with worse clinical prognosis NSCLC. However, effects on drug resistant still not well illustrated. Materials and methods Effects cells were checked by CCK-8 kit. Gene protein variations measured real-time PCR western blot analysis, respectively. Results Our present data confirmed that expression was significantly increased in NSCLC tissues. In addition, mRNA elevated doxorubicin (Dox) resistance when compared their corresponding sensitivity parental cells. Overexpression can down-regulate Dox up-regulate ABCC1, while has no effect ABCB1. Knockdown ABCC1 Dox-resistant Visfatin increase phosphorylation nuclear localization Akt LY294002 decrease multidrug protein-1 (MRP1) Chromatin immunoprecipitation assays showed overexpression binding promoter both A549 H1793 Conclusions These via activation Akt/MRP1. It indicated inhibition signals might be a promising therapeutic strategy for management chemoresistance patients.
sci-hub.se 参考文章(24)
Xiu-bao Chang, Molecular Mechanism of ATP-Dependent Solute Transport by Multidrug Resistance-Associated Protein 1 Methods in Molecular Biology. ,vol. 596, pp. 223- 249 ,(2010) , 10.1007/978-1-60761-416-6_11
B. Kalyanaraman, Joy Joseph, Shashi Kalivendi, Suwei Wang, Eugene Konorev, Srigiridhar Kotamraju, Doxorubicin-induced apoptosis: Implications in cardiotoxicity Molecular and Cellular Biochemistry. ,vol. 234, pp. 119- 124 ,(2002) , 10.1007/978-1-4615-1087-1_13
Roger G. Deeley, Susan P.C. Cole, Substrate recognition and transport by multidrug resistance protein 1 (ABCC1) FEBS Letters. ,vol. 580, pp. 1103- 1111 ,(2006) , 10.1016/J.FEBSLET.2005.12.036
Radu C. Oita, Dudley Ferdinando, Steve Wilson, Christopher Bunce, Dawn J. Mazzatti, Visfatin induces oxidative stress in differentiated C2C12 myotubes in an Akt- and MAPK-independent, NFĸB-dependent manner Pflügers Archiv - European Journal of Physiology. ,vol. 459, pp. 619- 630 ,(2010) , 10.1007/S00424-009-0752-1
Raghu Adya, Bee K. Tan, Anu Punn, Jing Chen, Harpal S. Randeva, Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis Cardiovascular Research. ,vol. 78, pp. 356- 365 ,(2008) , 10.1093/CVR/CVM111
A Singh, J Settleman, EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer Oncogene. ,vol. 29, pp. 4741- 4751 ,(2010) , 10.1038/ONC.2010.215
R Abdul-Ghani, V Serra, B Györffy, K Jürchott, A Solf, M Dietel, R Schäfer, The PI3K inhibitor LY294002 blocks drug export from resistant colon carcinoma cells overexpressing MRP1 Oncogene. ,vol. 25, pp. 1743- 1752 ,(2006) , 10.1038/SJ.ONC.1209201
Lindsey Enewold, Leah E. Mechanic, Elise D. Bowman, Yun-Ling Zheng, Zhipeng Yu, Glenwood Trivers, Anthony J. Alberg, Curtis C. Harris, Serum Concentrations of Cytokines and Lung Cancer Survival in African Americans and Caucasians Cancer Epidemiology, Biomarkers & Prevention. ,vol. 18, pp. 215- 222 ,(2009) , 10.1158/1055-9965.EPI-08-0705
Caitriona Holohan, Sandra Van Schaeybroeck, Daniel B. Longley, Patrick G. Johnston, Cancer drug resistance: an evolving paradigm Nature Reviews Cancer. ,vol. 13, pp. 714- 726 ,(2013) , 10.1038/NRC3599
Gergely Szakács, Jill K. Paterson, Joseph A. Ludwig, Catherine Booth-Genthe, Michael M. Gottesman, Targeting multidrug resistance in cancer Nature Reviews Drug Discovery. ,vol. 5, pp. 219- 234 ,(2006) , 10.1038/NRD1984